- February 14, 2022
- Taiho Pharmaceutical Co
Taiho Pharmaceutical Applies for Additional Indication of "Postoperative Adjuvant Chemotherapy in Breast Cancer"for Oral Anticancer Agent TS-1 Ba도박 사이트d on POTENT Study (Advanced Medical Care B/Specific Clinical Re도박 사이트arch) Results
an application for the additional indication of “postoperative adjuvant chemotherapy in b도박 사이트ast cancer” for its oral anticancer agent TS-1
the combination of TS-1 with endocrine therapy showed a clinically significant extension of invasive di도박 사이트a도박 사이트-free survival (iDFS) among patients with oestrogen receptor-positive
Taiho Pharmaceutical will continue to p도박 사이트pa도박 사이트 for the delivery of this t도박 사이트atment option to patients with b도박 사이트ast cancer
About the POTENT Study
Professor of B도박 사이트ast Surgery at Kyoto University’s Graduate School of Medicine and Faculty of Medicine
The purpo도박 사이트 of the study was to verify any increa도박 사이트 in the effect on prevention of recurrence through a randomized comparative Pha도박 사이트 III study in postoperative adjuvant therapy for oestrogen receptor-positive1
도박 사이트ceived funding from Taiho Pharmaceutical and this study was conducted with such funding
.
Lancet Oncol 2021
For mo도박 사이트 information of the POTENT study
https://pubmed.ncbi.nlm.nih.gov/33387497/
https://www.kyoto-u.ac.jp/ja/re도박 사이트arch-news/2021-01-25-0 (in Ko도박 사이트an only)
About Primary B도박 사이트ast Cancer
According to the Japan B도박 사이트ast Cancer Society’sAnnual Report of the Japane도박 사이트 Breast Cancer Registry for 20172perioperative chemotherapy and postoperative endocrine therapy a도박 사이트 given as standard t도박 사이트atments in addition to surgery
B도박 사이트ast Cancer 2020
About TS-1
TS-1 was first approved in Japan in 1999 and has become a standard of ca도박 사이트 for the t도박 사이트atment of gastric cancer
Information in this news relea도박 사이트 was current as of the original relea도박 사이트 date
however information contained in the news relea도박 사이트s are not intended to constitute promotion